“Multiple myeloma red flag”的搜索结果，显示 31-40 项，共有 10975 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Alternate Doses And Dosing Schedules Of Belantamab Mafodotin For The Treatment Of Triple-Class Recurrent And/or Refractory Multiple Myeloma. Jacksonville ...

2. 血液科- 临床试验- 妙佑医疗国际

   Inclusion Criteria are the following: age ≥ 18, blood cancer diagnosis (including B-ALL, multiple myeloma, and lymphoma), receiving a CAR-T product, able to ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Inclusion Criteria are the following: age ≥ 18, blood cancer diagnosis (including B-ALL, multiple myeloma, and lymphoma), receiving a CAR-T product, able to ...

4. 血液科- 临床试验- 妙佑医疗国际

   Inclusion Criteria are the following: age ≥ 18, blood cancer diagnosis (including B-ALL, multiple myeloma, and lymphoma), receiving a CAR-T product, able to ...

5. 脑肿瘤项目- 临床试验- 妙佑医疗国际

   ... multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no ...

6. 血液科- 临床试验- 妙佑医疗国际

   Inclusion Criteria are the following: age ≥ 18, blood cancer diagnosis (including B-ALL, multiple myeloma, and lymphoma), receiving a CAR-T product, able to ...

7. 血液科- 临床试验- 妙佑医疗国际

   Inclusion Criteria are the following: age ≥ 18, blood cancer diagnosis (including B-ALL, multiple myeloma, and lymphoma), receiving a CAR-T product, able to ...

8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   A Study To Evaluate APG2575 Combined With Novel Therapeutic Regimens To Treat Subjects With Relapsed Or Refractory Multiple Myeloma And Immunoglobulin Light ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   A Study of JNJ‐68284528 Out‐of‐Specification (OOS) for Commercial Release in Patients with Multiple Myeloma. Rochester, Minn. The purpose of this study is to ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... Multiple Myeloma That Is Resistant To Current Standard Of Care Treatments ... multiple myeloma. Linvoseltamab has previously been studied as a single agent ...